PATENT CLAIM ANALYSIS

Application Number: 16087320
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-04
Patent Classification: ["514", "300000"]

Abstract:
The invention relates to compounds of Formula (I): wherein R 1 , R 2  and R 3  are as defined in the description and claims, or pharmaceutically acceptable salts thereof, having α v β 6  integrin antagonist activity. The invention also relates to pharmaceutical compositions including a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and to the use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof in therapy, including in the treatment of a disease or condition for which an α v β 6  integrin antagonist is indicated, in particular the treatment of idiopathic pulmonary fibrosis.

Claim (Index 33):
The compound or pharmaceutically acceptable salt thereof according to  claim 32 , wherein one of R 1  and R 2  is hydrogen and the other is selected from 2-methoxypropoxy and (1-methoxy-2-methylpropan-2-yl)oxy.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 97.0
- Lexical Diversity: 1.98333
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15514414', '15514399', '16007584', '15922674', '15514407']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.819544384847329
- 35 USC 102 Novelty (BERT): 0.5655294540039482
- Combined Prediction Score: 0.7941428917629909
- Mean Citation Score: 466.401492
- Max Citation Score: 478.53427
- Similarity Product: 311.80608639600155

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test